Tony Fiorino is a seasoned biotechnology executive with a wealth of experience in clinical development and regulatory strategy, currently serving as a Clinical Development and Strategy Consultant at Alchimia Partners. In this role, Tony leverages his extensive background in drug development, spanning from late-stage preclinical...
Tony Fiorino is a seasoned biotechnology executive with a wealth of experience in clinical development and regulatory strategy, currently serving as a Clinical Development and Strategy Consultant at Alchimia Partners. In this role, Tony leverages his extensive background in drug development, spanning from late-stage preclinical to phase 4 clinical trials, to provide high-level strategic insights and operational guidance to biopharma companies. His expertise encompasses a diverse range of therapeutic areas, including oncology, inflammatory and immune diseases, and neurology, with a strong focus on various modalities such as small molecules, biologics, cell therapies, and medical devices.
At Alchimia Partners, Tony is instrumental in shaping clinical and regulatory strategies at both the portfolio and program levels. He plays a pivotal role in the execution of clinical trials across all phases, ensuring that study designs are robust and compliant with Good Clinical Practice (GCP) standards. His proficiency in clinical study design and operational considerations enables him to navigate complex regulatory landscapes, from pre-IND submissions to Biologics License Applications (BLA). Additionally, Tony is actively involved in due diligence projects, providing critical assessments that inform investment decisions and strategic partnerships for biopharma and medical device startups, including academic spin-outs.
With a keen eye for financial analysis and strategic planning, Tony also serves as an expert witness on drug development issues, addressing the materiality of data and public disclosures. His multifaceted skill set not only enhances the clinical development processes of his clients but also positions him as a trusted advisor in the biotechnology industry, driving innovation and fostering growth in a rapidly evolving landscape.
